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Introduction: Use of synthetic cannabinoids (SC) has recently emerged as a new drug epidemic. Our
emergency departments (EDs) received a surge of SC users presenting with lethargy and bradycardia,
contrasting prior reports of SC-induced tachycardia and agitation.Our goal was to describe these novel
presentations and characterize the compounds.
Methods: We present a case series of patients with SC intoxication who presented to our toxicology service
covering two tertiary care EDs between 2/11/2015 and 6/23/2015. A retrospective chart review recorded initial
vital signs, chief complaint and clinical course. Urine, blood and xenobiotic samples were analyzed using
either liquid chromatography/mass spectrometry or gas chromatography/mass spectrometry. We compared
resulting spectra against databases containing numerous SCs or metabolites and scored based on a
reference comparison.
Results: Between 2/11/2015 and 6/23/2015, we identified 141 visits. Males comprised 139 visits (age
range 21-68 years; median 35, interquartile range 20). Sixty-eight percent presented with lethargy or loss of
consciousness. Hypotension (SBP <90 mmHg) and bradycardia (HR<60 bpm) were seen in 10% and 24%
of visits, respectively. While most patients were discharged after observation, three were admitted to the
intensive care unit and seven to telemetry. Admissions were for vital sign instability, bradycardia requiring
pacing, prolonged sedation and respiratory failure requiring mechanical ventilation.
Laboratory analysis revealed SC in the XLR-11 family in 18/36 drug, 9/12 blood, and 23/31 urine samples.
Carboxamide indazole derivative (CID) family compounds were detected in 13/36 drug samples, 21/31 urine
samples, but no blood samples; 11/31 drug samples contained both XLR-11 and CID. Other compounds
detected included PB-22 and nicotine. No JWH compounds, opiates, imidazoline receptor agonists,
benzodiazepines or other sedative-hypnotics were detected.
Conclusion: Unlike their predecessors, novel SC may be associated with significant central nervous system
depression and bradycardia. While prior reports indicated that SC mostly contained JWH compounds, none
were detected in these samples. The most commonly identified compounds in this series were CID and alkyl
SC derivatives, such as INACA compounds and XLR-11. These tend to be full agonists at the cannabinoid
receptor and are presumably more potent. The lack of other depressants suggests that the clinical findings are
due to the combination of these compounds and not coingestants or adulterants. SC intoxication should be
considered for patients with undifferentiated psychomotor depression and bradycardia. [West J Emerg Med.
2018;19(3)567-572.]
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INTRODUCTION
Synthetic cannabinoids (SC) are a class of drugs that are
becoming increasingly popular throughout the United States
and Europe. Also known as “K2,” “spice,” spike,” or “legal
marijuana,” SC are causing intoxication requiring emergency
department (ED) visits in epidemic and unparalleled numbers.1
Patients present with a wide array of symptoms, ranging from
nausea and vomiting to confusion, agitation, short-term memory
loss, cognitive impairment, psychosis, seizures, arrhythmias,
strokes and even death.2 SC have often been associated with
sympathomimetic effects such as mydriasis, hypertension and
tachycardia.2 We present a case series of patients with SC
intoxication who presented atypically with central nervous
system (CNS) and cardiovascular depression over a five-month
period; in addition, we present an analysis of blood, urine and
SC samples using mass spectrometry. Intoxication with SC
products should be considered for patients with undifferentiated
psychomotor depression and bradycardia in addition to the
excitatory effects previously described.
BACKGROUND
In early 2015 our suburban, tertiary care EDs experienced a
large influx of patients presenting with lethargy and
psychomotor depression, often requiring admission to the
telemetry or intensive care units and rarely requiring intubation.
The patients usually experienced sudden and complete
resolution of symptoms after several hours in an obtunded state.
Large cohorts of these patients simultaneously presented from a
nearby psychiatric center that provided inpatient, outpatient and
residential services. The increased volume of intoxications
exacerbated ED crowding. Patients later admitted to SC use,
and some produced samples of the plant material. Questions
arose regarding the potential contamination of these substances
with other agents, such as clonidine or digoxin, or whether these
presentations were due to newer generation SC.
We selected cases for this series from the toxicology consult
service database for patients suspected of SC use. Blood and
urine samples were collected from the patients when possible.
The unknown drug samples were analyzed and compared to a
reference database to identify the compounds present.
MATERIALS AND METHODS
We included two tertiary care EDs in our case series. In
total, 141 ED visits were selected by toxicologists from the
consult service database based on abnormal triage vitals,
history of SC use or an obtunded mental state upon
presentation. Twelve blood and 31 urine samples were
collected. The 36 samples of plant material provided by
patients were collected and analyzed using liquid
chromatography/mass spectrometry and gas chromatography/
mass spectrometry (GC/MS). The samples were not correlated
with specific patients. This retrospective chart review was
approved by an institutional review board.
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Population Health Research Capsule
What do we already know about this issue?
Synthetic cannabinoid intoxication has
emerged as an epidemic, and can present
with a wide array of gastrointestinal,
neuropsychiatric and cardiovascular
symptoms.
What was the research question?
Are bradycardia and central nervous
system (CNS) depression associated
with novel synthetic cannabinoids, or
coingestants or adulterants?
What was the major finding of the study?
Novel synthetic cannabinoids were detected
with no coingestants and are associated
with CNS depression and bradycardia.
How does this improve population health?
Synthetic cannabinoid intoxication should be
considered for patients with undifferentiated
CNS depression and bradycardia.

Standards and Reagents
We purchased chemical reagents, including ethyl acetate,
methanol, water, and formic acid from VWR International
(Bridgeport, NJ). All solvents were high performance liquid
chromatography grade or better.
Sample Preparation
Samples were extracted with organic solvent and
concentrated to isolate any drugs present on the plant material.
Briefly, 5 mg aliquots of an unknown plant material, or 100 μL
of submitted blood/urine, were transferred to screwtop
centrifuge tubes. Two mL of ethyl acetate were added and the
samples were thoroughly mixed. Samples were extracted for
10 minutes on a nutating mixer at 24 revolutions per minute.
The solvent was transferred to clean test tubes and the extracts
were evaporated to dryness under nitrogen at 45°C. Samples
were reconstituted in 50 μL methanol and 50 μL 0.1% formic
acid in water and transferred to conical autosampler vials for
analysis by liquid chromatography time-of-flight (TOF) mass
spectrometry. Similarly, samples were reconstituted in 50 μL
ethyl acetate for GC/MS confirmation analysis. Biological
samples underwent a 20-minute room temperature hydrolysis
period prior to liquid-liquid extraction.
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Liquid Chromatography Conditions
We used an Agilent Technologies 1290 liquid
chromatograph (LC) equipped with a Zorbax Eclipse Plus
C-18 column (2.1mm x 50mm x 1.8μm) for chromatographic
separation of the unknown plant material extract. The LC
columns were maintained at 50°C in the thermostated column
compartment. Mobile phases consisted of 0.1% formic acid in
deionized water (A) and 100% methanol (B). The mobile
phase flow rate was set at 0.7 mL/min. Initial mobile phase
conditions were held at 0%B for 0.5 minutes then increased to
95%B over five minutes. Mobile phase conditions returned to
initial starting conditions for a final run time of six minutes.

available, unknown compounds were confirmed as positive by
comparison to a known reference material.

Time-of-Flight Mass Spectrometry Conditions
We operated an Agilent Technologies 6230 TOF mass
spectrometer with a Jetstream electrospray source in positive ion
mode with the following common parameters: nitrogen drying
gas temperature 350°C; nitrogen sheath gas temperature 400°C;
nitrogen drying gas flow 10 L/min; nitrogen sheath gas flow 11 L/
min; nebulizer pressure 45 psi; capillary voltage 4000 V; and
nozzle voltage 1000 V. Accurate mass spectra were acquired at a
rate of 1 spectra per second over the range of 100 – 1700 m/z.
TOF Data Analysis
We compared all acquired spectra against the Agilent
Technologies Forensic Toxicology PCD Accurate Mass
Database of over 7,500 compounds. All spectra were scored
based on deviation from expected exact mass assignment
(ΔPPM), chromatographic retention time, and peak abundance.
Scores greater than 90% match were considered positive.
Where available, unknown compounds were confirmed as
positive by comparison to a known reference material.
Gas Chromatography Mass Spectrometry Conditions
We used an Agilent Technologies 7980A series gas
chromatograph equipped with an HP-5MS column (30m x
0.25mm x 0.25μm), a 5975C series mass selective detector and
a 7693 series autoinjector module for chromatographic
separation of the unknown plant material extract. The transfer
line temperature was 295°C. The oven program consisted of an
equilibration time of 0.5 minutes, initial temperature of 100°C,
ramp of 15°C/minute to a final temperature of 325°C. The total
run time was 20 minutes. The inlet mode was splitless with a
temperature of 265°C and an injection volume of 1μL.
GC/MS Data Analysis
We compared all acquired spectra against the Scientific
Working Group for the Analysis of Seized Drugs
(SWGDRUG) database. All spectra were scored based on the
search quality of the generated spectrum in comparison to the
reference spectrum. We considered search quality scores
greater than or equal to 90% positively detected based on
chromatographic retention time, and peak abundance. Where
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RESULTS
We identified 141 patient visits from 2/11/2015 to
6/23/2015 (Table 1). Of these patients, 139 (98%) were male
with a median age of 35 (range 21-68 years old). Ninety-seven
(68%) of the patients presented with lethargy or an altered
level of consciousness. A smaller proportion presented with
hypotension (systolic blood pressure < 90 mmHg) (10%) or
bradycardia (heart rate < 60 bpm) (24%).
We analyzed 36 drug samples (Table 2) and found that the
majority of them contained carboxamide indazole derivatives
(CID) or XLR-11, an alkyl derivative. Eleven of the samples
had both derivative classes detected in the mixture and 14 had
no SC identified.
We found that 24 of 31 urine samples tested positive for a
SC; 74% of urine samples contained XLR-11, and 35% contained
carboxamide indazole derivatives (CID). Nine of the 12 blood
samples (75%) contained suspected metabolite of XLR-11. None
of the blood samples tested positive for CID. There were no JWH
compounds, opioids, imidazoline receptor agonist or sedativehypnotics detected in any of the material, urine or blood samples.
DISCUSSION
Hundreds of distinct SC compounds have been identified.2
SCs are responsible for a rapidly growing number of
presentations to EDs throughout the U.S. in the past several
years.1 SC use causes intense highs and has become popularized
due to accessibility, affordability and limited detectability in
common drug screens.3 Intoxications often present in clusters due
to local distribution of a single product and great variability in the
herbal mixtures. One study found a range of 2.3-22.9 mg/g of
cannabimimetics in the herbal mixtures.4 In addition, SC have
been found to be more potent than Δ9-THC;2 the SC 5F-ADBPINACA, a CID compound similar to a SC detected in our study,
is over 1,000 times more potent than Δ9-THC.5
In March 2011 the U.S. Department of Justice categorized

Table 1. Patients presenting with symptoms of synthetic
cannabinoid intoxication.
Total number
%
Total visits

141

100

Male visits

139

98

Lethargy/LOC

97

68

Hypotension (<90 SBP)

14

10

Bradycardia (<60 HR)

34

24

4

3

ICU admissions

Telemetry admissions
10
LOC, loss of consciousness; ICU, intensive care unit.
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Table 2. Analyses of samples for presence of synthetic cannabinoids.
Sample (total)

Any SC (%)

XLR-11 (%)

CID (%)

XLR-11 and CID (%)

Nicotine (%)

No SC definitively identified (%)

Drug (36)

22 (61)

18 (50)

13 (36)

11 (31)

5 (14)

14 (39)

Blood (12)

9 (75)

9* (75)

Not detected

Not detected

Not detected

3 (25)

20 (65)

Not detected

7 (23)

Urine (31)
24 (77)
23* (74)
21 (68)
CID, carboxamide indazole derivatives, SC, synthetic cannabinoids.
*Suspected metabolite of XLR-11 (UR-144 compounds).

the five most commonly abused SCs (JWH-018, JWH-073,
JWH-200, CP-47,497 and its C8 homolog) as Schedule I
drugs under 21 U.S.C.811(h) of the Controlled Substances
Act.6,7,8 As local outbreaks continued, the novel compounds
(detected in this study) were identified and added to the
Controlled Substances Act.
ED visits increased from 11,406 in 2010 to 28,531 in
2011.9,10 Visits from patients 12-17 years old more than
doubled from 3,780 to 7,584, while visits from patients18-20
years old increased from 1,881 to 8,212.9,10 In 2011, SCs were
the second most commonly used drug in the 10th grade and the
third most common in eighth grade following marijuana and
inhalants.2,11 Despite the federal ban on SCs that year, there
was no decline in frequency of use in high school students the
following year. However, use declined in each of the next
three years.11 Users of SCs vary greatly in both demographics
and motivation, but are typically males aged 13-59, most with
polydrug use and are found in larger, urban populations.2,12
SCs are known to interact with the cannabinoid receptors,
CB1 and CB2, leading to changes in levels of multiple
neurotransmitters including acetylcholine, dopamine,
noradrenaline, glutamine and GABA.2 Genetic polymorphisms in
enzymes responsible for metabolism of SCs can lead to increased
blood levels of the parent compound and prolonged duration of
action, and therefore a potential increased risk of adverse
events.10,13 In addition, many SC metabolites retain biological
activity.10,13 Combination of these metabolites with accumulation
of the parent drug creates complex pharmacodynamics, especially
when the multitude of other compounds typically found within
herbal mixtures is considered.
SCs have been reported to exhibit a wide array of effects.
CNS effects include psychosis, anxiety, agitation, irritability,
memory changes, sedation, confusion and hallucinations,14 in
addition to lowering the seizure threshold in susceptible
individuals.15 Reported cardiovascular effects include
tachycardia, chest pain, dysrhythmias, myocardial ischemia13
and cerebrovascular accident caused by embolisms due to
cardiac arrhythmias or reversible cerebral vasoconstriction
syndrome.16,17 In an analysis of a Centers for Disease Control
and Prevention report of 3,573 calls to poison control for
SC-related adverse events, the most common effects were
agitation (35%), tachycardia (29%), drowsiness or lethargy
(26%), vomiting (16%), and confusion (4%).1
Western Journal of Emergency Medicine

In early 2010, JWH-018 was detected in 100% of SC
products. However, as legislation regarding SCs changed in
2010 and 2011, the incidence of JWH-018 decreased, while
similar yet compositionally distinct compounds appeared. By
the end of 2012, JWH-018 was not detected in samples, and
XLR-11 became the most common SC detected,18 as exhibited
in our sample analysis.
In our case series, CID and alkyl SC derivatives, such as
INACA compounds and XLR-11,19 were the most commonly
detected with no opiates, imidazoline receptor agonists,
benzodiazepines or other sedative-hypnotics detected that
might explain the atypical presentations. Sixty-one percent of
the confiscated products contained a SC and 31% contained
both XLR-11 and CID. Seventy-five percent of blood samples
and 77% of urine samples tested positive for SC. Unlike their
predecessors, novel SC appear to be associated with
significant CNS depression and bradycardia. The compounds
detected in our case series tended to be full agonists at the
cannabinoid receptor and are more potent than Δ9-THC.20 The
lack of other CNS and cardiovascular depressants suggests
that the clinical findings are due to the combination of these
compounds and not coingestants or adulterants.
It is important to note that many substances detected in the
plant samples were not detected in the blood or urine samples.
Some examples include 5-Fluoro-NNEI 2’-naphthyl isomer,
5-fluoropentylindole, NM-2201 and NPB-22. There are multiple
explanations for these findings. The patient may have used SC
products that were not included in our plant samples and
therefore would not be associated with the urine and blood
samples. It is also possible that the metabolites of the compound
were not in the database or that the level was below the LC TOF
detection limits. Furthermore, the metabolite may have been
metabolized to a common XLR metabolite that was detected, or
the drug had already been eliminated from the body.
LIMITATIONS
Our case series demonstrates some of the severe effects
these novel compounds can cause. However, the study has a
number of important limitations. First, the selection of patients
was based on the judgment of our ED team and toxicologists
based on abnormal vital signs, subjective history from the
patient, presentation of decreased mental status and clinical
judgment. Many intoxicated patients may have been evaluated
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and treated without being included in the study. In addition,
patients may have had altered mental status for reasons other
than SC intoxication and may have been erroneously included
in the study because their ED arrival was associated with other
patients with SC intoxication. Although there were 141 visits,
several patients with recurrent intoxications were included as
multiple visits in the study.
The SC samples were provided by patients, but it should
not be assumed that the specific sample was necessarily the
cause of their intoxication. Furthermore, the samples were
collected anonymously, without designation to a specific
patient, and therefore we were unable to identify which of the
patients presenting with bradycardia tested positive for certain
compounds. This significantly diminished our ability to
conclude that certain types of SC are associated with more
profound presentations of bradycardia and psychomotor
depression. Lastly, the majority of the patients presented from
a large, nearby psychiatric center. The patients often presented
as groups, possibly due to simultaneous drug use with the
same sample. This patient population tends to have multiple
comorbidities, and members may be taking neuroleptic
medications that may increase the opportunity for interactions
with the cannabinoids. This is a population with an increased
risk of substance use, and therefore the results of our case
series cannot necessarily be extrapolated to other populations.
CONCLUSION
SC products are inexpensive, easily obtained, avoid
common drug detection screens and cause a wide array of signs
and symptoms. The changing composition of available SCs
corresponds to the variability exhibited in patient presentations.
SC intoxication should be considered for patients with varied
clinical effects, including undifferentiated psychomotor
depression, loss of consciousness, hypotension and bradycardia.
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